1. Home
  2. DHT vs DFTX Comparison

DHT vs DFTX Comparison

Compare DHT & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DHT Holdings Inc.

DHT

DHT Holdings Inc.

HOLD

Current Price

$19.17

Market Cap

2.1B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$17.99

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DHT
DFTX
Founded
2005
N/A
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
DHT
DFTX
Price
$19.17
$17.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$16.33
$40.25
AVG Volume (30 Days)
4.0M
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.99%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.73
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.00
$14.62
52 Week High
$20.55
$18.70

Technical Indicators

Market Signals
Indicator
DHT
DFTX
Relative Strength Index (RSI) 82.15 57.80
Support Level $10.96 $16.19
Resistance Level N/A $18.09
Average True Range (ATR) 0.80 1.02
MACD 0.25 0.07
Stochastic Oscillator 74.72 95.57

Price Performance

Historical Comparison
DHT
DFTX

About DHT DHT Holdings Inc.

DHT Holdings Inc is a crude oil tanker company. Its fleet trades internationally and consists of crude oil tankers in the VLCC. The group generates revenues from time charter and spot market operations. It operates through integrated management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from the shipping revenues.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: